Modern GLP-1 receptor agonists are increasingly replacing traditional treatment approaches in many patient populations, offering effective blood glucose regulation, substantial weight-loss benefits, and reduced cardiovascular risk
Furthermore, localized renal neoplasia without changes in renal function is neither considered a risk factor for gastroparesis nor grade 1 obesity.( 1 ) Based on the mechanism of action of semaglutide and other drugs in the same class, the most frequent side effects are weight loss and nausea.( 3 ) While there is no scientific evidence that elucidates the perioperative management of patients using semaglutide and other glucagon-like peptide-1 receptor agonists, it is prudent to consider the high risk of pulmonary aspiration in all of these cases, regardless of fasting time
Back Vecchio, i, Tornali, C, Bragazzi, NL, et al (23 Oct 2018) 'The Discovery of Insulin: An important milestone in the history of medicine', Frontiers in Endocrinology , 9, 613
However, given the novelty of this therapeutic approach, the available evidence may be influenced by publication bias and early optimism, and long-term mechanistic and clinical outcome data remain limited
